Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency.

Renal insufficiency (RI) has been shown to be associated with increased major adverse cardiovascular events after percutaneous coronary intervention. We reviewed the impact of RI on the pathogenesis of coronary artery disease and outcomes after percutaneous coronary intervention in the form of drug-eluting stent (DES) implantation in these high-risk patients. We searched the English-language literature indexed in MEDLINE, Scopus, and EBSCO Host research databases from 1990 through January 2009, using as search terms coronary revascularization, drug-eluting stent, and renal insufficiency. Studies that assessed DES implantation in patients with various degrees of RI were selected for review. Most of the available data were extracted from observational studies, and data from randomized trials formed the basis of a post hoc analysis. The outcomes after coronary revascularization were less favorable in patients with RI than in those with normal renal function. In patients with RI, DES implantation yielded better outcomes than did use of bare-metal stents. Randomized trials are needed to define optimal treatment of these high-risk patients with coronary artery disease.

[1]  Qi Zhang,et al.  Impact of moderate or severe renal insufficiency on long-term outcomes in patients undergoing drug-eluting stent based coronary intervention. , 2009, International journal of cardiology.

[2]  D. Chae,et al.  The Association between Kidney Function, Coronary Artery Disease, and Clinical Outcome in Patients Undergoing Coronary Angiography , 2009, Journal of Korean medical science.

[3]  C. Reid,et al.  Rates of stent thrombosis in bare-metal versus drug-eluting stents (from a large Australian multicenter registry). , 2008, The American journal of cardiology.

[4]  R. Califf,et al.  The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. , 2008, American heart journal.

[5]  Seung‐Jung Park,et al.  Impact of significant chronic kidney disease on long-term clinical outcomes after drug-eluting stent versus bare metal stent implantation. , 2008, International journal of cardiology.

[6]  J. Ivanov,et al.  Impact of renal insufficiency on angiographic, procedural, and in-hospital outcomes following percutaneous coronary intervention. , 2008, The American journal of cardiology.

[7]  Josepa Mauri,et al.  Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). , 2008, Journal of the American College of Cardiology.

[8]  W Scott Beattie,et al.  Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.

[9]  Hiroshi Takahashi,et al.  Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. , 2008, Circulation journal : official journal of the Japanese Circulation Society.

[10]  K. Goto,et al.  Impact of impaired renal function and diabetes on long-term prognosis in patients undergoing primary angioplasty for acute coronary syndrome. , 2008, Internal medicine.

[11]  N. Kressin,et al.  Chronic Kidney Disease Is Associated with Angiographic Coronary Artery Disease , 2007, American Journal of Nephrology.

[12]  S. Takagi,et al.  Comparison of long-term clinical outcome after sirolimus-eluting stent implantation in patients with and without hemodialysis. , 2007, International heart journal.

[13]  I. Komuro,et al.  Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[14]  A. Colombo,et al.  Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment , 2007, Circulation.

[15]  G. Vanzetto,et al.  Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. , 2007, Journal of the American College of Cardiology.

[16]  S. Markwell,et al.  Short- and long-term clinical outcomes of coronary drug-eluting stent recipients presenting with chronic renal disease. , 2007, The Journal of invasive cardiology.

[17]  H. Fujita,et al.  [Limitation on efficacy of sirolimus-eluting stent implantation in patients on hemodialysis]. , 2007, Journal of cardiology.

[18]  G. Nakazawa,et al.  Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus‐eluting stents , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[19]  G. Stone,et al.  Late stent thrombosis: Considerations and practical advice for the use of drug‐eluting stents: A report from the Society for Cardiovascular Angiography and Interventions drug‐eluting stent task force , 2007 .

[20]  A. Kraśniak,et al.  Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  W. Laskey,et al.  Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. , 2006, The Journal of invasive cardiology.

[22]  I. Komuro,et al.  Images in cardiovascular medicine. Damage to polymer of a sirolimus-eluting stent. , 2006, Circulation.

[23]  S. Rajagopalan,et al.  Peripheral Arterial Disease in Patients With End-Stage Renal Disease: Observations From the Dialysis Outcomes and Practice Patterns Study (DOPPS) , 2006, Circulation.

[24]  A. Garg,et al.  Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. , 2006, JAMA.

[25]  S. Steinhubl,et al.  Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. , 2006, The Journal of invasive cardiology.

[26]  Qi Zhang,et al.  Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention. , 2006, Chinese medical journal.

[27]  D. Malhotra,et al.  HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Platelet Dysfunction and End‐Stage Renal Disease , 2006 .

[28]  N. Weissman,et al.  Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. , 2006, The Journal of invasive cardiology.

[29]  Seiki Nagata,et al.  Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. , 2006, Journal of the American College of Cardiology.

[30]  K. Kent,et al.  Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents. , 2006, The American journal of cardiology.

[31]  D. Chew,et al.  Morbidity, mortality and economic burden of renal impairment in cardiac intensive care , 2006, Internal medicine journal.

[32]  Mark E. Williams.  Coronary revascularization in diabetic chronic kidney disease/end-stage renal disease: a nephrologist's perspective. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[33]  K. Kent,et al.  Correlates and Long-Term Outcomes of Angiographically Proven Stent Thrombosis With Sirolimus- and Paclitaxel-Eluting Stents , 2006, Circulation.

[34]  Christopher T. Chan,et al.  Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. , 2006, American heart journal.

[35]  R. Dietz,et al.  Percutaneous Coronary Intervention in Patients with End-Stage Renal Disease , 2006, Kidney and Blood Pressure Research.

[36]  G. Stone,et al.  Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial. , 2005, American heart journal.

[37]  Carmine Zoccali,et al.  Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. , 2005, Journal of the American Society of Nephrology : JASN.

[38]  I. Iakovou,et al.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. , 2005, JAMA.

[39]  A. Kastrati,et al.  Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. , 2005, JAMA.

[40]  E. Topol,et al.  Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). , 2005, The American journal of cardiology.

[41]  P. Serruys,et al.  Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. , 2005, The American journal of cardiology.

[42]  G. Stone,et al.  Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. , 2005, The American journal of cardiology.

[43]  P. Serruys,et al.  Treatment of coronary artery disease in dialysis patients with sirolimus-eluting stents: 1-year clinical follow-up of a consecutive series of cases. , 2004, The Journal of invasive cardiology.

[44]  B. Davis,et al.  Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. , 2004, Journal of the American College of Cardiology.

[45]  R. Gupta,et al.  The renal patient with coronary artery disease: current concepts and dilemmas. , 2004, Journal of the American College of Cardiology.

[46]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[47]  P. Teirstein,et al.  Contribution of Stent Underexpansion to Recurrence After Sirolimus-Eluting Stent Implantation for In-Stent Restenosis , 2004, Circulation.

[48]  J. Moses,et al.  Sirolimus-eluting stents vs. standard stents in patients with stenosis in a native coronary artery , 2004 .

[49]  J. J. Griffin,et al.  Impact of Renal Insufficiency in Patients Undergoing Primary Angioplasty for Acute Myocardial Infarction , 2003, Circulation.

[50]  Shing‐Jong Lin,et al.  Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. , 2003, European heart journal.

[51]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[52]  K. Eagle,et al.  Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. , 2003, Journal of the American College of Cardiology.

[53]  J. Tcheng,et al.  Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). , 2003, The American journal of cardiology.

[54]  A. Collins,et al.  Comparative Survival of Dialysis Patients in the United States After Coronary Angioplasty, Coronary Artery Stenting, and Coronary Artery Bypass Surgery and Impact of Diabetes , 2002, Circulation.

[55]  A. Jaffe,et al.  Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination , 2002, Annals of Internal Medicine.

[56]  R. Califf,et al.  Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes , 2002, Circulation.

[57]  M. Bell,et al.  The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. , 2002, Journal of the American College of Cardiology.

[58]  J. Senges,et al.  Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab. , 2002, The American journal of cardiology.

[59]  G. Stone,et al.  Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[60]  J. Teruel,et al.  Phospholipase A2 activity in platelets of patients with uremia , 2002, Platelets.

[61]  G. Breithardt,et al.  Long-Term Outcome after Percutaneous Transluminal Coronary Angioplasty in Patients with Chronic Renal Failure with and without Diabetic Nephropathy , 2001, Nephron.

[62]  S. Yusuf,et al.  Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial , 2001, Annals of Internal Medicine.

[63]  I. Palacios,et al.  Are Patients With Renal Failure Good Candidates for Percutaneous Coronary Revascularization in the New Device Era? , 2000, Circulation.

[64]  S. Mezzano,et al.  Hemostatic Disorder of Uremia: The Platelet Defect, Main Determinant of the Prolonged Bleeding Time, Is Correlated with Indices of Activation of Coagulation and Fibrinolysis , 1996, Thrombosis and Haemostasis.

[65]  H. Shimokawa,et al.  Granulocyte activation in restenosis after percutaneous transluminal coronary angioplasty. , 1996, Japanese circulation journal.

[66]  Yuh-Feng Lin,et al.  Cytokine production during hemodialysis: effects of dialytic membrane and complement activation. , 1996, American journal of nephrology.

[67]  M. Gawaz,et al.  Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. , 1994, Journal of the American Society of Nephrology : JASN.